Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Cash from Discontinued Operations (2016 - 2017)

Lisata Therapeutics (LSTA) has disclosed Cash from Discontinued Operations for 4 consecutive years, with 69.0 as the latest value for Q4 2017.

  • For the quarter ending Q4 2017, Cash from Discontinued Operations fell 100.0% year-over-year to 69.0, compared with a TTM value of 69.0 through Sep 2018, down 99.99%, and an annual FY2017 reading of 638000.0, down 114.0% over the prior year.
  • Cash from Discontinued Operations was 69.0 for Q4 2017 at Lisata Therapeutics, down from 4856569.0 in the prior quarter.
  • Across five years, Cash from Discontinued Operations topped out at 4856569.0 in Q2 2017 and bottomed at 5494638.0 in Q1 2017.